Medicine guide
Xigris
·
- Prescription status not stated
- Blood, clotting and anaemia
- Active substance
- Drotrecogin alfa (activated)
- Used in
- Blood, clotting and anaemia
- Made by
- Eli Lilly Nederland B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care. The use of Xigris should be considered mainly in situations when therapy can be started within 24 hours after the onset of organ failure (for further information see section 5.1).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Eli Lilly Nederland B.V. |
|---|---|
| Active substance | Drotrecogin alfa (activated) |
| Used in | Blood, clotting and anaemia |
| Classification | B01AD10 · Blood, clotting and anaemia |
| Authorised on | 2002-08-22 |
| Last updated by the regulator | 2012-02-21 |
| EMA product number | EMEA/H/C/000396 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).